Patient-derived dendritic cells transduced with an α-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells

Liver International

Volumn 26, Issue 3, 2006, Pages 369-379

  González Carmona, Maria A ^a   Märten, Angela ^b   Hoffmann, Per ^a   Schneider, Carlo ^a   Sievers, Elisabeth ^a   Schmidt Wolf, Ingo G H ^a   Sauerbruch, Tilman ^a   Caselmann, Wolfgang H ^a,c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Bavarian State Ministry of the Environment   (Germany)

Author keywords

Adenovirus; Dendritic cells; Hepatocellular carcinoma; Human fetoprotein; Immunotherapy

Indexed keywords

ALPHA FETOPROTEIN; CYTOKINE;

ADENOVIRUS VECTOR; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL STIMULATION; COCULTURE; CYTOLYSIS; CYTOTOXICITY; DENDRITIC CELL; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; KILLER CELL; LIVER CELL CARCINOMA; LYMPHOCYTE CULTURE; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ALPHA-FETOPROTEINS; ANTIGEN PRESENTATION; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; TRANSDUCTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; TUMOR CELLS, CULTURED;

EID: 33644808620     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01235.x     Document Type: Article

References (57)

1. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15: 225-36.
2. Di Bisceglie A M, Carithers R L Jr., Gores G J. Hepatocellular carcinoma. Hepatology 1998; 28: 1161-5.
3. Abelev G I, Eraiser T L. Cellular aspects of alpha-fetoprotein reexpression in tumors. Semin Cancer Biol 1999; 9: 95-107.
4. Butterfield L H, Meng W S, Koh A, et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 2001; 166: 5300-8.
5. Meng W S, Butterfield L H, Ribas A, et al. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime- adenovirus boost genetic vaccination. Cancer Res 2001; 61: 8782-6.
6. Wang X P, Liu G Z, Song A L, Li H Y, Liu Y. Antitumor immunity induced by DNA vaccine encoding alpha-fetoprotein/heat shock protein 70. World J Gastroenterol 2004; 10: 3197-200.
7. Hanke P, Serwe M, Dombrowski F, Sauerbruch T, Caselmann W H. DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther 2002; 9: 346-55.
8. Vollmer C M Jr., Eilber F C, Butterfield L H, et al. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999; 59: 3064-7.
9. Schuler G, Steinman R M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997; 186: 1183-7.
10. Steinman R M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-96.
11. Banchereau J, Steinman R M. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
12. Märten A, Schöttker B, Ziske C, et al. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9 protein. J Immunother 2000; 23: 464-72.
13. Banchereau J, Palucka A K, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451-8.
14. Tatsumi T, Takehara T, Kanto T, et al. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 2001; 61: 7563-7.
15. Lee W C, Wang H C, Jeng L B, et al. Effective treatment of small murine hepatocellular carcinoma by dendritic cells. Hepatology 2001; 34: 896-905.
16. Schmidt-Wolf I G, Lefterova P, Johnston V, et al. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 1994; 87: 453-8.
17. Schmidt-Wolf I G, Negrin R S, Kiem H P, Blume K G, Weissman I L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139-49.
18. Lee C S. Lymphocytes and their subsets in the peripheral blood of hepatocellular carcinoma patients. J Formos Med Assoc 1991; 90: 626-30.
19. Saibara T, Maeda T, Miyazaki M, Onishi S, Yamamoto Y. Depressed immune function in patients with cirrhosis before emergence of hepatocellular carcinoma. Hepatology 1993; 18: 315-9.
20. Kakumu S, Ito S, Ishikawa T, et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 2000; 15: 431-6.
21. Hanke P, Rabe C, Serwe M, et al. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP- specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 2002; 37: 949-55.
22. Um S H, Mulhall C, Alisa A, et al. Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol 2004; 173: 1772-8.
23. Fallaux F J, Kranenburg O, Cramer S J, et al. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-22.
24. Koyama Y, Taketa K, Azuma M, Yamamoto R, Fujimoto S, Nishi S. Biochemical characterization of alpha-fetoprotein and other serum proteins produced by a uterine endometrial adenocarcinoma. Jpn J Cancer Res 1996; 87: 612-7.
25. He T C, Zhou S, da Costa L T, Yu J, Kinzler K W, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-14.
26. Graham F L, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3: 207-20.
27. Nishimura N, Nishioka Y, Shinohara T, et al. Novel centrifugal method for simple and highly efficient adenovirus-mediated green fluorescence protein gene transduction into human monocyte-derived dendritic cells. J Immunol Methods 2001; 253: 113-24.
28. Blomberg K, Granberg C, Hemmila I, Lovgren T. Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence. J Immunol Methods 1986; 86: 225-9.
29. Nishimura N, Nishioka Y, Shinohara T, et al. Novel centrifugal method for simple and highly efficient adenovirus-mediated green fluorescence protein gene transduction into human monocyte-derived dendritic cells. J Immunol Methods 2001; 253: 113-24.
30. Butterfield L H, Koh A, Meng W, et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 1999; 59: 3134-42.
31. Butterfield L H. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 2004; 127: S232-41.
32. Saeki A, Nakao K, Nagayama Y, et al. Diverse efficacy of vaccination therapy using the alpha-fetoprotein gene against mouse hepatocellular carcinoma. Int J Mol Med 2004; 13: 111-6.
33. Homma S, Toda G, Gong J, Kufe D, Ohno T. Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 2001; 36: 764-71.
34. Märten A, Renoth S, von Lilienfeld-Toal M, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 2001; 86: 1029-37.
35. Nestle F O, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.
36. Verneris M R, Baker J, Edinger M, Negrin R S. Studies of ex vivo activated and expanded CD8+NK-T cells in humans and mice. J Clin Immunol 2002; 22: 131-6.
37. Wan Y, Bramson J, Carter R, Graham F, Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997; 8: 1355-63.
38. Wang F S, Liu M X, Zhang B, et al. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 2002; 8: 464-8.
39. Wood G W, Holladay F P, Turner T, Wang Y Y, Chiga M. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 2000; 48(2): 113-20.
40. Schmidt-Wolf I G, Finke S, Trojaneck B, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999; 81(6): 1009-16.
41. Märten A, Ziske C, Schöttker B, et al. Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived from pancreatic and colorectal cancer patients. Int J Colorectal Dis 2000: 15: 197-205.
42. Arthur J F, Butterfield L H, Roth M D, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4: 17-25.
43. Zhong L, Granelli-Piperno A, Choi Y, Steinman R M. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999; 29: 964-72.
44. Meng W S, Butterfield L H, Ribas A, et al. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. Mol Immunol 2000; 37: 943-50.
45. Tüting T, Steitz J, Bruck J, et al. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J Gene Med 1999; 1: 400-406.
46. Tanaka F, Hashimoto W, Robbins P D, Lotze M T, Tahara H. Therapeutic and specific antitumor immunity induced by co- administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18. Gene Ther 2002; 9: 1480-6.
47. Kianmanesh A, Hackett N R, Lee J M, Kikuchi T, Korst R J, Crystal R G. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther 2001; 12: 2035-49.
48. Song W, Tong Y, Carpenter H, Kong H L, Crystal R G. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen. Gene Ther 2000; 7: 2080-6.
49. Crystal R G, McElvaney N G, Rosenfeld M A, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51.
50. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 2001; 22: 102-7.
51. Korst R J, Mahtabifard A, Yamada R, Crystal R G. Effect of adenovirus gene transfer vectors on the immunologic functions of mouse dendritic cells. Mol Ther 2002; 5: 307-315.
52. Rouard H, Leon A, Klonjkowski B, et al. Adenoviral transduction of human 'clinical grade' immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. J Immunol Methods 2000; 241: 69-81.
53. Irie M, Homma S, Komita H, et al. Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice. Int J Cancer 2004; 111: 238-4
54. Chan R C, Xie H, Zhao G P, Xie Y. Dendritomas formed by fusion of mature dendritic cells with allogenic human hepatocellular carcinoma cells activate autologous cytotoxic T lymphocytes. Immunol Lett 2002; 83: 101-9.
55. Ludewig B, Ochsenbein A F, Odermatt B, Paulin D, Hengartner H, Zinkernagel R M. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191: 795-804.
56. Shirai M, Watanabe S, Nishioka M. Defective immunological functions associated with abnormal lymphokine- activated killer activity in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1990; 5: 542-548
57. Saibara T, Onishi S, Sakaeda H, Yamamoto Y. Defective function of lymphokine-activated killer cells and natural killer cells in patients with hepatocellular carcinoma. Hepatology 1989; 9: 471-6.